Vistagen Therapeutics Stock Performance

VTGN Stock  USD 2.94  0.08  2.80%   
The entity has a beta of 0.1, which indicates not very significant fluctuations relative to the market. As returns on the market increase, VistaGen Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding VistaGen Therapeutics is expected to be smaller as well. At this point, VistaGen Therapeutics has a negative expected return of -0.0906%. Please make sure to validate VistaGen Therapeutics' downside variance, as well as the relationship between the accumulation distribution and price action indicator , to decide if VistaGen Therapeutics performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days VistaGen Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, VistaGen Therapeutics is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more

Actual Historical Performance (%)

One Day Return
2.8
Five Day Return
(0.34)
Year To Date Return
(11.45)
Ten Year Return
(98.77)
All Time Return
(99.80)
Last Split Factor
1:30
Last Split Date
2023-06-07
1
Vistagen Therapeutics Inc Q2 2025 Earnings Report Preview What to Expect
11/06/2024
2
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
11/07/2024
3
VistaGen Therapeutics, Inc. Reports Q2 Loss, Misses Revenue Estimates
11/08/2024
4
Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc
11/15/2024
5
Vistagen Therapeutics, Inc. Shares Sold by Great Point Partners LLC - MarketBeat
11/27/2024
6
Acquisition by Anderson Cynthia Lynn of 2592 shares of VistaGen Therapeutics at 2.5075 subject to Rule 16b-3
12/31/2024
7
Acquisition by Smith Mark Alan of 5000 shares of VistaGen Therapeutics at 0.748 subject to Rule 16b-3
01/17/2025
Begin Period Cash Flow16.6 M
  

VistaGen Therapeutics Relative Risk vs. Return Landscape

If you would invest  322.00  in VistaGen Therapeutics on November 2, 2024 and sell it today you would lose (28.00) from holding VistaGen Therapeutics or give up 8.7% of portfolio value over 90 days. VistaGen Therapeutics is currently does not generate positive expected returns and assumes 3.6534% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than VistaGen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days VistaGen Therapeutics is expected to under-perform the market. In addition to that, the company is 4.29 times more volatile than its market benchmark. It trades about -0.02 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.14 per unit of volatility.

VistaGen Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for VistaGen Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as VistaGen Therapeutics, and traders can use it to determine the average amount a VistaGen Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0248

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsVTGN

Estimated Market Risk

 3.65
  actual daily
32
68% of assets are more volatile

Expected Return

 -0.09
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.02
  actual daily
0
Most of other assets perform better
Based on monthly moving average VistaGen Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of VistaGen Therapeutics by adding VistaGen Therapeutics to a well-diversified portfolio.

VistaGen Therapeutics Fundamentals Growth

VistaGen Stock prices reflect investors' perceptions of the future prospects and financial health of VistaGen Therapeutics, and VistaGen Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on VistaGen Stock performance.

About VistaGen Therapeutics Performance

By examining VistaGen Therapeutics' fundamental ratios, stakeholders can obtain critical insights into VistaGen Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that VistaGen Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 829.89  737.69 
Return On Tangible Assets(4.08)(4.28)
Return On Capital Employed 8.95  14.87 
Return On Assets(4.08)(4.28)
Return On Equity 8.98  12.43 

Things to note about VistaGen Therapeutics performance evaluation

Checking the ongoing alerts about VistaGen Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for VistaGen Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
VistaGen Therapeutics generated a negative expected return over the last 90 days
VistaGen Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 1.06 M. Net Loss for the year was (29.36 M) with profit before overhead, payroll, taxes, and interest of 876.3 K.
VistaGen Therapeutics currently holds about 51.99 M in cash with (25.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25.
Evaluating VistaGen Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate VistaGen Therapeutics' stock performance include:
  • Analyzing VistaGen Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether VistaGen Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining VistaGen Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating VistaGen Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of VistaGen Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of VistaGen Therapeutics' stock. These opinions can provide insight into VistaGen Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating VistaGen Therapeutics' stock performance is not an exact science, and many factors can impact VistaGen Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether VistaGen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VistaGen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vistagen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vistagen Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.74)
Revenue Per Share
0.029
Quarterly Revenue Growth
(0.34)
Return On Assets
(0.39)
Return On Equity
(0.62)
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.